Issue 35, 2021

Salts, solvates and hydrates of the multi-kinase inhibitor drug pazopanib with hydroxybenzoic acids

Abstract

The marketed formulation of pazopanib (PAZ) suffers from low and variable bioavailability because of its poor dissolution rate and photostability issues. The drug falls under Biopharmaceutics Classification System (BCS) class II of low solubility and good permeability. The hydrogen bonds and supramolecular interactions in crystalline forms of PAZ with hydroxybenzoic acids (HBAs) and dihydroxybenzoic acids (DHBAs), as well as its salts are analyzed. Ten X-ray crystal structures of PAZ which include the reference drug, a tetrahydrofuran solvate (PAZ·THF) and eight salts with HBAs/DHBAs are reported. There is proton transfer from the carboxylic group of the coformer acid to the most basic nitrogen atom of the 2-aminopyrimidine ring of PAZ in all cases. Two salts were crystallized in neat form, while the remaining six are solvates and hydrates. The crystal structure of PAZ is stabilized by sulfonamide and 2-aminopyrimidine homosynthons of N–H⋯O and N–H⋯N hydrogen bonds in an R22(8) ring motif. PAZ·HBA/DHBA salts consistently contain the aminopyridinium⋯carboxylate N+–H⋯O synthon of the R22(8) ring. The sulfonamide homosynthon of PAZ is disrupted in preference to the formation of N–H⋯O and N–H⋯N hydrogen bonds in salt structures. The presence of an additional basic nitrogen atom in the indazole ring of PAZ promotes hydration and solvation through the O–H⋯N hydrogen bond. Whereas the formation of salts is desirable for pharmaceutical formulation, the inclusion of adventitious solvent and/or water molecules with hydroxybenzoic acid coformers in the cocrystal-salt products is a limitation for this class of coformers. The stability problem faced with hydrates and solvates of PAZ·HBA/DHBA salts means that their formation must be carried out by strictly anhydrous procedures. The consistent occurrence of the aminopyridinium⋯carboxylate N+–H⋯O ring synthon is discussed in relation to the previous results of Aakeröy, Nangia and Zaworotko groups on similar acid–base multi-component systems.

Graphical abstract: Salts, solvates and hydrates of the multi-kinase inhibitor drug pazopanib with hydroxybenzoic acids

Supplementary files

Article information

Article type
Paper
Submitted
12 Jūn. 2021
Accepted
28 Jūl. 2021
First published
29 Jūl. 2021

CrystEngComm, 2021,23, 5994-6011

Salts, solvates and hydrates of the multi-kinase inhibitor drug pazopanib with hydroxybenzoic acids

S. K. Rai, D. Baidya and A. K. Nangia, CrystEngComm, 2021, 23, 5994 DOI: 10.1039/D1CE00785H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements